Immunotherapy AdvancesImmunologyPeer-reviewed journal article
Lag3 and PD-1 pathways regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activation
Lozan SheriffiD, Alastair CoplandiD, David A.J. LeckyiD, Reygn DoneiD, L. S. George, Emma K. JenningsiD, Sophie RouvrayiD, Thomas A.E. ElliotiD, Elizabeth Jinks, Lalit PallaniD, David BendingiD
- Citations
- 5
- FWCI
- 0.77
- Field percentile
- top 31%
Abstract
Lag3 and PD-1 are immune checkpoints that regulate T cell responses and are current immunotherapy targets. Yet how they function to control early CD4+ T cell activation remains unclear. Here, we show that the PD-1 and Lag3 pathways exhibit layered control of the early CD4+ T cell activation process, with the effects of Lag3 more pronounced in the presence of PD-1 pathway co-blockade (CB). RNA-sequencing revealed that CB drove an early NFAT-dependent transcriptional profile, including promotion of ICOShi T follicular helper (Tfh) cell differentiation. NFAT pathway inhibition abolished CB-induced upregulation of NFAT-dependent co-receptors ICOS and OX40, whilst unaffecting the NFAT-independent gene Nr4a1. Mechanistically, Lag3 and PD-1 pathways functioned additively to regulate the duration of T cell receptor (TCR) signals during CD4+ T cell re-activation. Our data therefore reveal that PD-1 and Lag3 pathways converge to additively regulate TCR signal duration and NFAT-dependent transcriptional activity during early CD4+ T cell re-activation. HighlightsO_LIPD-1 and Lag3 pathways exhibit layered control of early CD4+ T cell activation C_LIO_LITheir co-blockade enhances NFAT-dependent TCR transcriptional programmes C_LIO_LIInhibition of NFAT signalling reverses the functional effects of PD-1 and Lag3 co-blockade C_LIO_LIMechanistically, PD-1 and Lag3 function to additively regulate TCR signal duration during re-activation of CD4+ T cells C_LI
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell signaling & trafficking
- research focus: transcription & RNA processing
- research focus: cell type annotation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antigen and Checkpoint Receptor Recalibration of T Cell Receptor Signal Strength
T. A. E. Elliot, E. K. Jennings, … D. Bending·bioRxiv·Mar 2, 2021
- FGL-1 binding to LAG-3 inhibits T cell activation via disruption of CD28 and TCR signaling
Samantha Nyovanie, Anika Hashem, … Michelle Krogsgaard·bioRxiv·Aug 5, 2025
- PD-1 and CTLA-4 exert additive control of effector regulatory T cells
J. A. Perry, Z. Lanzar, … C. A. Hunter·bioRxiv·Jul 22, 2022
- TCR-dependent and TCR-independent in-vitro T cell activation generate distinct functional, metabolic, and cytokine programs: Protein kinase C signalling augments anti-CD3+anti-CD28 responses
Nikita S. Ramteke, Dipankar Nandi·bioRxiv·Jul 20, 2026
- Differential Nr4a1 and Nr4a3 expression discriminates tonic from activated TCR signalling events in vivo
E. K. Jennings, T. A. E. Elliot, … D. Bending·bioRxiv·Jan 15, 2020
- Phosphatidylserine binding regulates TIM-3 effects on T cell receptor signaling
C. M. Smith, A. Li, … M. A. Lemmon·bioRxiv·May 7, 2021